PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
45.33
ESG score below 80% of Biotechnology median of 60.04. Michael Burry would check for potential stranded assets and regulatory compliance issues.
27.98
Environmental score below 80% of Biotechnology median of 56.46. Michael Burry would check for potential carbon tax exposure and regulatory compliance costs.
51.75
Social score 80-90% of Biotechnology median of 63.21. Martin Whitman would look for hidden social liabilities and reputational risks.
56.27
Governance score 90-95% of Biotechnology median of 61.95. John Neff would demand higher returns to compensate for below-average governance oversight.